Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-28 Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
26-09-25	US$2.400	-10.11%	52,013
26-09-24	US$2.670	+1.71%	15,746
26-09-23	US$2.625	-1.13%	28,145
26-09-22	US$2.655	+1.78%	13,722
26-09-21	US$2.608	+8.42%	19,493

Delayed Quote NYSE

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - NYSE 16:00:00 2026-09-25 EDT			5-day change	1st Jan Change
0.1600 ^USD	-10.11%		-93.35%	-98.18%

08-20	Top Premarket Decliners	MT
08-13	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	2.35M 2.06M 1.95M 1.78M 3.32M 225M 3.35M 23.31M 9.03M 115M 8.83M 8.64M 370M	P/E 2024	-1.53x	P/E 2025	-4.39x
Enterprise Value	-294K -258K -244K -222K -416K -28.19M -419K -2.92M -1.13M -14.4M -1.1M -1.08M -46.29M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	76.25%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
NYSE	MTNB	Delayed
CBOE	MTNB	Real-time

08-20	Top Premarket Decliners	MT
08-13	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-14	Top Premarket Decliners	MT
07-13	Azurity Pharmaceuticals, Inc. entered into the stock purchase agreement to acquire Matinas Biopharma Nanotechnologies, Inc. from Matinas BioPharma Holdings, Inc. (NYSEAM : MTNB) for $21.5 million.	CI
07-13	Matinas BioPharma to Merge With GH Power; Signs Deal to Sell Subsidiary, Lead Product Candidate	MT
06-16	Matinas BioPharma Files $150 Million Mixed Shelf Registration	MT
05-08	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Matinas BioPharma Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
01-23	Matinas BioPharma Holdings Inc Keith Kucinski resigns as CFO effective January 17, 2026	RE
01-23	Jerome D. Jabbour to Assume the Duties of Principal Accounting Officer of Matinas BioPharma Holdings, Inc	CI
01-23	Matinas Biopharma Holdings, Inc. Appoints Jerome D. Jabbour as Interim Chief Financial Officer, Effective January 22, 2026	CI
11-21	Matinas Biopharma Holdings Inc - CFO Keith Kucinski resigns effective January 17, 2026 - SEC filing	RE

Matinas BioPharma Holdings, Inc. Stock

Stocks

MTNB

US5768103039

Biotechnology & Medical Research

Valuation: Matinas BioPharma Holdings, Inc.

Chart: Matinas BioPharma Holdings, Inc.

Latest news: Matinas BioPharma Holdings, Inc.

Analysts' recommendations: Matinas BioPharma Holdings, Inc.

Press Releases: Matinas BioPharma Holdings, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Matinas BioPharma Holdings, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24-10-31	Maxim Downgrades Matinas BioPharma to Hold From Buy	MT
21-05-11	Matinas BioPharma : Piper Sandler Cuts Matinas BioPharma Holdings to Neutral From Overweight, Price Target to $0.90 From $4	MT
21-03-30	Matinas BioPharma : HC Wainwright Adjusts Price Target on Matinas BioPharma Holdings to $3 From $4, Maintains Buy Rating	MT

09-14	GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output	AQ
09-04	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	AQ
07-30	GH Power and TKMS Continue to Explore Clean Energy Collaboration in Support of Canada’s Future Patrol Submarine Project	BU
07-28	Growth Catalysts: TOON, LVWR, MTNB, LGHL Offer Double-Digit Gain Potential	AQ
07-13	GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma	BU

1 day	-10.11%
1 week	-93.35%
Current month	-94.60%
1 month	-94.67%
3 months	-98.34%
6 months	-98.10%
Current year	-98.18%

1 week	0.15	2.7
1 month	0.15	3.07
Current year	0.15	13.6
1 year	0.15	29.85
3 years	0.15	667.5
5 years	0.15	1,087.5
10 years	0.15	2,992.5

Manager	Title	Age	Since
Jerome Jabbour CEO	Chief Executive Officer	52	2018-03-15
Susan Johansson CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jerome Jabbour CHM	Chairman	52	2025-03-13
Evelyn D'An BRD	Director/Board Member	61	2025-02-04
Keith Murphy BRD	Director/Board Member	55	2025-03-10

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/30/25	Jerome Jabbour	Free	Chief Executive Officer	70,100	1.3780%
4/30/25	Keith Murphy	Free	Director	11,600	0.2280%
4/30/25	Edward Neugeboren	Free	Director	11,600	0.2280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATINAS BIOPHARMA HOLDINGS, INC.	-10.11%	-93.35%	-99.44%	-99.84%	2.35M
WUXI APPTEC CO., LTD.	-3.30%	+1.50%	+57.79%	+85.24%	72.26B
ARGENX SE	+1.25%	-3.01%	+37.83%	+84.34%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+2.12%	+5.26%	+35.69%	+18.97%	27.73B
INSMED INCORPORATED	-3.06%	-1.81%	-14.01%	+354.94%	25.73B
BIONTECH SE	-0.75%	+2.56%	+0.45%	-4.46%	24.75B
GENMAB A/S	+0.40%	+0.75%	+23.72%	-9.50%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+150.24%	+323.16%	15.06B
EXELIXIS, INC.	+0.36%	-0.34%	+48.98%	+162.10%	14.41B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.21%	+1.17%	-3.95%	+484.12%	14.23B
Average	-1.46%	+0.37%	+23.73%	+139.91%	27.52B
Weighted average by Cap.	-0.77%	+0.31%	+38.16%	+126.05%

	2024	2025
Net sales	-	-
Net income	-24.25M -21.28M -20.1M -18.32M -34.29M -2.32B -34.53M -241M -93.15M -1.19B -91.05M -89.08M -3.82B	-10.34M -9.08M -8.57M -7.81M -14.63M -992M -14.73M -103M -39.74M -507M -38.84M -38M -1.63B
Net Debt	-4.39M -3.85M -3.64M -3.32M -6.21M -421M -6.25M -43.54M -16.86M -215M -16.48M -16.13M -691M	-2.64M -2.32M -2.19M -2M -3.74M -254M -3.77M -26.23M -10.16M -130M -9.93M -9.72M -416M